Project: Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations

Acronym Variation (Reference Number: 10. JTC-2016_156)
Duration 01/05/2017 - 30/04/2020
Project Topic Some forms of heart failure are often very difficult to treat. Patients who have a mutation in Lamin A/C can develop a form of heart disease that often does not respond well enough to existing therapies. VARIATION aims to develop a new technology to inhibit mutated Lamin A to halt the disease. The project will test this new RNA based technology in human cell that are derived from stem cells obtained from patients that actually carry the disease. VARIATION is expected to provide the first steps towards a treatment that is applicable to most patients that carry such a mutation and can halt progression of the associated heart failure.
Network ERA-CVD
Call ERA-CVD Joint Transnational Call 2016

Project partner

Number Name Role Country
1 University of Amsterdam Coordinator Netherlands
2 Charité – University Hospital Berlin, Campus Virchow (CVK) Partner Germany
3 Technion Israel Institute of technology Partner Israel
4 Hospital Pitié-Salpêtrière Partner France